- LCTX Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
10-K/A Filing
Lineage Cell Therapeutics (LCTX) 10-K/A2018 FY Annual report (amended)
Filed: 1 May 19, 5:00pm
Exhibit 31.2
CERTIFICATION PURSUANT TO
SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Brandi L. Roberts, certify that:
1. | I have reviewed this Amendment No. 2 on Form 10-K/A to the annual report on Form 10-K of BioTime, Inc.; and |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. |
Date: May 1, 2019
/s/ Brandi L. Roberts | |
Brandi L. Roberts | |
Chief Financial Officer | |
(principal financial officer and principal accounting officer) |
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.